Author

M. Brousseau

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1 Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Organism:E. coli· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

K. A. Henzler-Wildman· 2 shared P. J. Spreacker· 2 shared A. Aebi· 1 shared A. Graff Meyer· 1 shared A. Ianari· 1 shared A. Osmont· 1 shared A. Skepner· 1 shared B. Bajrami· 1 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

K. A. Henzler-Wildman

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Charge neutralization of the active site glutamates does not limit substrate binding and transport by EmrE

P. J. Spreacker, M. Brousseau, G. S. Hisao, M. Soltani, J. Davis, K. A. Henzler-Wildman

The paper tests whether charge neutralization of glutamates limits EmrE's substrate binding and transport, finding it does not.

bioRxiv · Aug 17, 2022 · PreprintBiophysics

Activating alternative transport modes in a multidrug resistance efflux pump to confer chemical susceptibility

P. J. Spreacker, N. E. Thomas, W. F. Beeninga, M. Brousseau, C. J. Porter, K. M. Hibbs, K. A. Henzler-Wildman

The paper shows that the E. coli SMR transporter EmrE can confer susceptibility to small-molecule substrates like harmane by triggering proton uniport, leading to antibiotic synergy.

bioRxiv · Dec 4, 2021 · PreprintBiochemistry

Loss of hepatic Lgr4 and Lgr5 promotes nonalcoholic fatty liver disease

E. Saponara, C. Penno, M. L. Matadamas Guzman, V. Brun, B. Fischer, M. Brousseau, Z.-Y. Wang, P. ODonnell, J. Turner, A. Graff Meyer, L. Bollepalli, G. dArio, G. Roma, W. Carbone, V. Orsini, , H. Ruffner

This study shows that deleting Lgr4/5 in mouse livers disrupts Wnt/β-catenin signaling, leading to fatty liver disease and fibrosis.

bioRxiv · Nov 22, 2021Physiology

Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction

D. C. McKinney, B. J. McMillan, M. Ranaghan, J. A. Moroco, M. Brousseau, Z. Mullin-Bernstein, M. O'Keefe, P. McCarren, M. F. Mesleh, K. M. Mulvaney, R. Singh, B. Bajrami, A. Skepner, D. E. Timm, D. Porter, , A. Ianari

The paper identifies a first-in-class inhibitor, BRD0639, that targets the PRMT5-PBM interaction, disrupting SAP binding and reducing substrate methylation in cancer cells.

bioRxiv · Feb 3, 2021 · PreprintCancer Biology